Startups

Avation Medical

Avation Medical develops wearable peripheral-nerve stimulation and digital-health technology for bladder symptoms. Its prescription Vivally System combines an ankle-worn garment and stimulator with a mobile application to deliver non-invasive electrical stimulation of the tibial nerve at home. Electromyographic sensors measure nerve activation, and proprietary control software continuously adjusts stimulation within a clinician-calibrated therapeutic range. The system treats urge urinary incontinence and urinary urgency associated with overactive bladder, pairing stimulation with behavioral support and symptom tracking. The U.S. FDA cleared Vivally through the 510(k) pathway, K220454, on April3,2023. The current company is led by co-founder, CEO and board member Manish Vaishya.

Team

Darren WennenChief Marketing Officer (appointed 2022; current status unconfirmed)

Jackie GerberrySenior Director, Finance (published March 2026)

Jason WhitingFormer Chief Executive Officer (appointment published November 2024)

Jill SchiaparelliCo-Founder; Former Chief Executive Officer; Director (published 2021, current board status unconfirmed)

Kevin WassersteinDirector (published 2021; current status unconfirmed)

Kimberly WilkinsonFormer Senior Director of Clinical Operations

Manish VaishyaChief Executive Officer, Co-Founder and Board Member

Michael HoffmanVice President of Market Access and Payer Relations (appointed 2024; current status unconfirmed)

Raymond HuggenbergerIndependent Director (appointed 2021; current status unconfirmed)

Renee SelmanIndependent Director (appointed 2021; current status unconfirmed)

Tom ShehabFormer Board Chair (published 2024)

Investments

$—2026-03-20	0 participations
$—2024-02-01	ShangBay Capital, Asahi Kasei Corp., Angelini Ventures, JobsOhio Ventures, Arboretum Ventures, Medtronic, Avestria Ventures

team@apexlogos.ai10 hours ago
Vivally is wearable transcutaneous tibial-nerve neuromodulation for urge urinary incontinence and urinary urgency associated with overactive bladder; this profile does not assert a brain implant or a broader FDA indication. FDA510(k)K220454 decision April3,2023: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K220454. Company leadership directory currently publishes only Manish Vaishya CEO/co-founder/director; own March20,2026release also names Jackie Gerberry SeniorDirectorFinance. Other named appointments are retained with explicit historical/current-unconfirmed titles; no complete unpublished workforce claimed. JillSchiaparelli and JasonWhiting are former CEOs; Thomas/TomShehab current own Arboretum biography lists Avation under previous portfolio involvement. 2021independent directors ReneeSelman/RaymondHuggenberger and KevinWasserstein membership is not asserted current. April2022company issuer names DarrenWennen ChiefMarketingOfficer; manager page calls DarrenWennan ChiefMedicalOfficer incorrectly, issuer prevails. KimberlyWilkinson own LinkedIn departure makes role historical. MichaelHoffman market-access professional is distinct from nativeMichaelHoffman Palamon founder/Santéadviser: qualified internal identity created and exact display restored. No guessed start/end dates. https://www.prnewswire.com/news-releases/avation-medical-raises-22m-from-impressive-line-up-of-new-global-investors-to-jump-start-sales-of-the-first-closed-loop-wearable-neuromodulation-technology-for-bladder-treatment-302051222.html explicitly says MORETHANUSD22m oversubscribedSeriesC and REMAINSOPEN on February1,2024; amount NULL is deliberate, not zero or exactly22m. Seven verified native institutional participants retained with NULLtickets; missing Tonkawa queued for a complete manager profile. March20,2026SeriesDsuccessfulclose https://www.avation.com/blog/avation-medical-announces-manish-vaishya-phd-as-chief-executive-officer-closes-series-d has undisclosed size and investors; none of the2024participants assigned to it. Actual Avestria10888 holding and SeriesCcheck proven; own FundIcard https://www.avestria.vc/avation-medical is not proof of which legal fund vehicle supplied the2024check. NativeMedtronic10316 canonical own corporate domain reused; bareGoldiMedtronic3738 not merged or duplicated. JobsOhioGrowthCapital former-program continuity corresponds to currentJobsOhioVentures10589, not a second institutional investor. AsahiKaseiCorp10398 exact disclosed parent used, not duplicate Ventures10395orTherapeutics10399. Authentic own headerSVG rendered unchanged toPNG and visually inspected. Founding year, exact investor tickets, unnamed Asahi/Angelini board representatives and historical legal predecessor alias Veressa are unproved and omitted.